Research programme: immunological disorder therapeutics - Ondek
Alternative Names: ImmBALANCE®; OND 86Latest Information Update: 28 Oct 2024
At a glance
- Originator Ondek
- Class Allergy immunotherapies; Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atopic dermatitis; Eczema; Food hypersensitivity; Hypersensitivity; Inflammation
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Atopic-dermatitis in Australia (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Food-hypersensitivity in Australia (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Allergy(Prevention) in Australia (PO)